Christopher Nirschl

5PUBLICATIONS
40CO-AUTHORS
TransgenesisInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 13, 2026
WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike "Non-Alpha" Muteins.

Christopher J Nirschl, Kulandayan K Subramanian, Heather R Brodkin

|Jul 29, 2025
PD-1 is requisite for skin TRM cell formation and specification by TGFβ.

K Sanjana P Devi, Eric Wang, Abhinav Jaiswal

|Apr 19, 2023
mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity.

Christopher J Nirschl, Heather R Brodkin, Celesztina Domonkos

|Apr 20, 2018
PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF.

Girija Goyal, Karrie Wong, Christopher J Nirschl

|Jul 16, 2017
Near-Infrared 1064 nm Laser Modulates Migratory Dendritic Cells To Augment the Immune Response to Intradermal Influenza Vaccine.

Kaitlyn Morse, Yoshifumi Kimizuka, Megan P K Chan

Pageof 1

Frequent Collaborators

3 joint publications

Niroshana Anandasabapathy

2 joint publications

William M Winston

2 joint publications

Heather R Brodkin

2 joint publications

Celesztina Domonkos